



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/706,759	11/12/2003	Gerald D. Cagle	2442	7815

7590

01/27/2005

Alcon Research, Ltd.  
Patrick M. Ryan(Q-148)  
R&D Counsel  
6201 So. Freeway  
Fort Worth, TX 76134-2099

EXAMINER

KIM, JENNIFER M

ART UNIT PAPER NUMBER

1617

DATE MAILED: 01/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

10/706,759

Applicant(s)

CAGLE ET AL.

Examiner

Jennifer Kim

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 07 October 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-10 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-10 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 2/9, 4/26, 8/6/04.
- ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: \_\_\_\_\_.

## DETAILED ACTION

### **Claims 1-10 are presented for Examination.**

#### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lanier et al. ( Clinical Therapeutics, July 2002) of record in view of Kim (U.S.Patent No. 5,976,573) and further in view of Ray et al. (Journal of Allergy and Clinical Immunology, 1999).

Lanier et al. teach the efficacy of combined fluticasone (nasal) and olopatadine (ophthalmic) in the treatment of allergic rhinoconjunctivitis (allergic rhinitis combined

Art Unit: 1617

with allergic conjunctivitis). (abstract, conclusion). Lanier et al. teach the effective amount of olopatadine (0.1%) for the treatment of rhinoconjunctivitis. (page 1165 left-hand column third paragraph).

Lanier et al. do not teach the composition comprising olopatadine and fluticasone in a single nasal aqueous composition, specified particle size of fluticasone, pH and viscosity.

Kim teaches aqueous-based pharmaceutical nasal spray comprising fluticasone comprising recommended viscosity of about 50 to 200 cp. (column 5, lines 17-20, column 4, lines 3-5). Kim teaches the spray comprising the pH fall within the range of about 4.5 to about 7.5. (column 6, lines 58-65). Kim teaches the range of the fluticasone to be utilized in the spray is about 0.001 to about 2 %wt. (column 4, lines 20-27). Kim teaches the particle size of the fluticasone should be no greater than about 50 microns; preferably the particles have an average size of about 1 to about 20 microns. (column 4, lines 15-19). Kim teaches symptoms of allergic rhinitis include nasal itch, congestion, runny nose, sneezing and watery eyes. (column 1, lines 17-25). Kim teaches the aqueous nasal spray affords numerous and important advantages in the treatment of a condition that involves application of a medicament to the surface of the mucosa which line the nasal cavities by delivering a medicament readily to the many portions of the nasal cavities where it can perform its pharmacological function. (column 3, lines 15-25).

Ray et al. report allergic rhinoconjunctivitis a condition with allergic rhinitis combined with allergic conjunctivitis. (text).

Art Unit: 1617

It would have been obvious to one of ordinary skill in the art to formulate fluticasone and olopatadine in a single aqueous nasal spray formulation for the treatment of allergic rhinitis because Lanier et al. teach that both combined treatment comprising fluticasone and olopatadine is effective and compatible for the treatment of rhinoconjunctivitis which includes the condition of allergic rhinitis as reported by Ray et al. and because the aqueous nasal sprays afford numerous and important advantages in the treatment of a condition including allergic rhinitis that involves delivering a medicament readily to the portions of the nasal cavities where it can perform its pharmacological function as taught by Kim. One would have been motivated to combine and formulate fluticasone and olopatadine in a single aqueous nasal spray formulation for the treatment of allergic rhinitis in order to achieve direct delivery of a active agents readily to many portion of the nasal cavities and successfully treat the symptoms of allergic rhinitis including nasal itch, congestion, runny nose, sneezing and watery eyes by administer directly to the target nasal tissues in a convenient single formulation.

For these reasons the claimed subject matter is deemed to fail to patentably distinguish over the state of the art as represented by the cited references. The claims are therefore properly rejected under 35 U.S.C. 103.


None of the claims are allowed.

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Sreenivasan Padmanabhan  
Supervisory Examiner  
Art Unit 1617

Jmk  
January 6, 2005